From the publisher feed

The FDA published its complete response letter to Summit Therapeutics explaining why it rejected the biotech's closely watched lung cancer drug:

Read the original at STAT ↗

Opens the original publisher page. Access, copyright and subscriptions are controlled by the publisher.

A useful next step

  1. Read the short publisher description here.
  2. Open the full report directly at the publisher.
  3. Compare this topic with other sources when useful.